India SEBI Regulatory Enforcement Actions — July 04, 2026
The sole filing in this stream pertains to Akums Drugs and Pharmaceuticals, where a subsidiary's GST penalty of INR 3.59 crore was overturned by the appellate authority. This is a low-materiality positive event with no financial impact. No other regulatory enforcement actions were reported in the period. The lack of multiple filings limits cross-company comparisons, but the resolution of this tax dispute is a minor positive for Akums.